China – based diagnostic specialist Shuwen Biotech Co., Ltd and its German wholly – owned subsidiary Cerca Biotech GmbH have entered into a collaboration agreement with Nottingham University Hospitals (NUH). The agreement is designed to bolster the clinical study, application, and promotion of Shuwen’s core product, MammaTyper. Financial details of the agreement were not disclosed.
About MammaTyper
MammaTyper is a real – time fluorescent quantitative PCR detection kit for molecular typing, suitable for patients with newly diagnosed or recurrent breast cancer. The kit offers several advantages over traditional immunohistochemistry (IHC), including greater objectivity, repeatability, accuracy, and simplicity. These features make MammaTyper a valuable tool for improving the diagnosis and treatment of breast cancer.
Shuwen Biotech’s Background and Partnerships
Founded in 2011, Shuwen Biotech has established high – profile international partnerships with institutions such as Yale University and Chicago University. These collaborations highlight Shuwen’s commitment to advancing diagnostic technologies and improving patient outcomes through innovative research and development.-Fineline Info & Tech
